Most women with newly-diagnosed advanced breast cancer are preferentially treated with a non-steroidal aromatase inhibitor (letrozole or anastrozole), with or without a CDK 4/6 inhibitor [7,8,9]. This evidence concerns the gene CYP19A1 and breast carcinoma.